OncoMatch/Clinical Trials/NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Is NCT05243797 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Teclistamab and Lenalidomide for multiple myeloma.
Treatment: Teclistamab · Lenalidomide — This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: induction therapy
have received induction +/- consolidation
Must have received: autologous stem cell transplant
as maintenance therapy following autologous stem cell transplantation
Cannot have received: maintenance therapy
Must not have received any maintenance therapy
Cannot have received: BCMA-directed therapy
Received any prior BCMA-directed therapy
Cannot have received: immune cell redirecting agent
Any previous therapy with an immune cell redirecting agent or gene modified adoptive cell therapy (eg, chimeric antigen receptor modified T cells, NK cells)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner University Medical Center Tucson, University of Arizona · Phoenix, Arizona
- UCLA Medical Center · Los Angeles, California
- University of California-Davis Cancer Center · Sacramento, California
- University of California, San Diego (UCSD) Medical Center · San Diego, California
- University of Colorado Hospital · Aurora, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify